The Canadian Top Ten Watch List of New and Emerging Health Technologies: Methods, Lessons Learned, and Impact Rosmin Esmail, MSc, CHE Chair for CNESH Director,

Slides:



Advertisements
Similar presentations
Outcomes of the 2008 Conference and Work of the Access to Medicines Working Group Will Delaat David Learmonth ChairmanDeputy Secretary Medicines AustraliaDepartment.
Advertisements

Derby Hospitals moving forward in the 21 st Century …. Dianne Prescott, Director of Strategy & Partnerships Future Strategy.
5th Annual PBM Pharmacy Informatics Conference
1 Purchaser/Supplier Global Relations: New Projects to Improve Health Care System Performance Transforming Purchaser/Supplier Cooperation to Improve Healthcare.
American College of Chest Physicians (ACCP) Health and Science Policy Committee Orientation Program Part #1 General Overview and Structure.
November 26, Fall Forum Alberta’s Pharmaceutical Strategy and Programs Policy Recommendations.
Presentation by Cambodian Participants Phuket, Thailand February 2012 Health Impact Assessment Royal Government of Cambodia.
Pricing and Reimbursement Policies 27. Pricing Policies Patented Medicines Patented Medicine Prices Review Board (PMPRB) monitors and sets the price of.
Project IMPACT IMPACT National Medical Association What African Americans Should Know About Clinical Trials You’ve Got the Power!
SEBs: “What do patients say? Presented by Cheryl L. Koehn 2015 CADTH Symposium Saskatoon, Saskatchewan April 14, 2015.
Institutionalizing HIA in Québec: Section 54 of the Public Health Act Dr. Alain Poirier, National Public Health Director and Assistant Deputy Minister.
CADTH Therapeutic Reviews
HTA from an Industry Perspective Janey Shin, Director of Medical Affairs Johnson & Johnson Medical Companies CADTH, 2015.
Canadian Network For Environmental Scanning in Health Cédric Jehanno Project manager – optimal use of drugs and horizon scanning at INESSS Vice-Chair of.
Collaboration for a Provincial Hospital Formulary: The New Brunswick Experience Faith Louis Regional Manager QI & Support, Pharmacy Services Horizon Health.
Evidence Access on the Front Lines of Healthcare: Harnessing the Potential of Wireless Devices CADTH Symposium 2015 Mollie Butler, RN, PhD. - Eastern Health.
The practice of knowledge transfer at CHSRF: Self-assessment tool “Executive training for research application” program Pierre Sauvé Director, Knowledge.
The Canadian Top 10 Watch List of New and Emerging Health Technologies Alain Boisvert, M.Sc (Pharm.) Vice-President, Market Access & Public Affairs April.
CADTH – CNESH Panel Presentation Representing Canada’s Medical Technology Industry April 13 th, 2015 Alison Drinkwater: Director of Public Affairs Baxter.
HTA & Medical Devices: An International Perspective Christina Farup, MD, MS | April 2015.
Michelle Boudreau, Vice President, Private Markets, March 11, 2015 Presentation to CADA.
Memorial Hermann Healthcare System Clinical Integration & Disease Management Dan Wolterman April 15, 2010.
Conference: Generic Drugs in Turkey and the EU THE PORTUGUESE MODEL FOR STIMULATING GENERIC COMPETITION IN THE EU June 2, 2005, Ankara, Turkey Rui Santos.
AHRQ’s Role in Comparative Effectiveness Carolyn M. Clancy, MD Director Agency for Healthcare Research and Quality Alliance for Health Reform Briefing.
CNESH: Top 10 Process ANDRA MORRISON 14 APRIL, 2015.
Interoperability to Support a Learning Health System HL7 Learning Health Systems Workgroup.
Global Advisory Panel (GAP) on Corporate Governance and Risk Management of Blood Services in Red Cross and Red Crescent Societies Introduction to the Global.
Stefan Franzén Introduction to clinical trials.
Benchmarking Canadian HTA Agency and Provincial Payer Decision-Making Allen N. 1,2, Liberti L. 2, Salek M.S. 1 1 Centre for socioeconomic research, School.
Experimental Cancer Medicine – the future of cancer care Rosie Davies (LECMC RP based at RLUH) Janet Davies (LECMC RP based at CCO)
2 Title Your Name Here Health Technology Center affiliate of The Institute for the Future.
Evidence-Based Public Health Nancy Allee, MLS, MPH University of Michigan November 6, 2004.
Potential Roles for Health Technology Assessment Agencies: Opportunities and Challenges for an Effective Health Technology Assessment Practice at the Meso.
HTA cooperation in the EU EPF workshop Jérôme Boehm 18 May 2010.
A Model for Translating Research into Practice in the United States - Mexico Border Region Howard J. Eng, MS, DrPH Director, Southwest Border Rural Health.
1 E-Health Source: Information Systems for Healthcare Management, 6th Edition Authors: Charles J. Austin and Stuart B. Boxerman Health Administration Press.
Secondary Translation: Completing the process to Improving Health Daniel E. Ford, MD, MPH Vice Dean Johns Hopkins School of Medicine Introduction to Clinical.
Supporting Informed Formulary Decision Making: CADTH’s Common Drug Review Denis Bélanger, Director, CADTH New Brunswick Stroke Summit November 27, 2010,
Cancer Centers In Clinical Trials Sandrine Marreaud Head of Medical Department.
BMH CLINICAL GUIDELINES IN EUROPE. OUTLINE Background to the project Objectives The AGREE Instrument: validation process and results Outcomes.
PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE PCORI Board of Governors Meeting Washington, DC September 24, 2012 Anne Beal, MD, MPH, Chief Operating Officer.
Canadian Best Practices Portal for Health Promotion and Chronic Disease Prevention April 22, 2008 Demetrios Angelis Public Health Agency of Canada.
The New Drug Development Process (www. fda. gov/cder/handbook/develop
The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.
FDA Regulation Economically Harmful & Morally Indefensible.
Access to drugs, Reducing bottlenecks Matt Cooper Business Development & Marketing Director NIHR Clinical Research Network
Health Technology Assessment for Pharmaceuticals and New Medical Technologies - Where are we now? The industry perspective Jenny Hughes, Director, Vaccines.
DEVELOPING TALENT GROWING VENTURES OPENING MARKETS Visit us at marsdd.com From HTA recommendatio n to adoption at scale APRIL 11, 2016 Zayna Khayat, Ph.D.
Standards and Competencies for Cancer Chemotherapy Nursing Practice in Canada: CANO/ACIO AN INTRODUCTION.
Expanding the Reach of Evidence in Nova Scotia Can we get the Evidence to Everyone? CADTH Symposium 2016 Lisa Farrell- Chair of DEANS ( NS Liaison CADTH)
Private and confidential Community Pharmacy Future Four-or-more medicines support service Update on progress and next steps Approved18 th June 2012 This.
Aarkstore - Metastatic Ovarian Cancer- Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 Category : Pharmaceuticals and Healthcare.
Annie Bilodeau Executive Director. Disclosure No conflict of interest.
Conferenceboard.ca Aligning, Foreseeing, and Optimizing HTA in Canada 2016 CADTH Symposium April 12, 2016 Dr. Gabriela Prada Director, Health Innovation.
OUR FOCUS FOR 2011 TO 2012 The CfWI produces quality intelligence to inform better workforce planning, that improves people’s lives.
Drug Development Process Stages involved in Regulating Drugs
IT Solutions – Improving Timely Access to Health Care
Strengthening the integration of gender in national and regional statistical strategies Proposed PARIS21 & UN Women collaboration.
NIHR Invention for Innovation (i4i)
The Health Services Research Centre and NAP5
19/05/2018 An introduction to Horizon Scanning Research & Intelligence Centre (HSRIC)
Variation in health state preferences across local and international populations: East doesn’t meet West CADTH symposium Panel Session April 12, 2016.
WELSH RISK POOL Vicky Langford.
World Health Organization
Dr Peter Groves MD FRCP Consultant Cardiologist
CADTH Overview Barb Shea, Vice-President, COMPUS
Health Technology Assessment in India
Realizing effective health technology assessment for the SA healthcare environment Praneet Valodia The BHF Southern African Conference July’07.
Research Orientation & Training for Investigators and Research Staff
EUnetHTA Assembly May 2018.
Presentation transcript:

The Canadian Top Ten Watch List of New and Emerging Health Technologies: Methods, Lessons Learned, and Impact Rosmin Esmail, MSc, CHE Chair for CNESH Director, Health Technology Assessment and Adoption Research, Innovation and Analytics Portfolio Alberta Health Servcies CADTH symposium, April 13, 2015

 Started in May  A Canadian collaborative network of organizations and individuals.  Identifies and shares information on new and emerging health technologies to support health care decision making and the appropriate adoption and use of effective and safe health technologies. Canadian Network for Environmental Scanning in Health

 To identify information on new, emerging, or new applications of health technologies, and to share this information across Canada.  To develop and promote methods for the identification, filtration and prioritization of new or emerging health technologies. Mandate

 Rosmin Esmail, Chair, Health Technology Assessment and Adoption, Research Innovation and Analytics Portfolio, Alberta Health Services  Cédric Jehanno, Vice-Chair, Institute national d’excellence on santé et services sociaux (INESSS)  Ron Goree, Past Chair  Nelson Millar, Office of Pharmaceuticals Management Strategies, Health Canada  Keith Keough, Healthcare Technology and Data Management, Eastern Health Region  Janet Martin, Health Technology Assessment for the Evidence-based Perioperative Clinical Outcomes Research (EPiCOR-HiTEC)  Gabriela Prada, Health Innovation, Policy and Evaluation, The Conference Board of Canada  Dagmara Chojecki, Institute for Health Economics  Mitch Levin, Programs for Assessment of Technology in Health Research Institute (PATH), McMaster University  Elena Lungu, Patent Medicines Prices Review Board  Nina Buscemi, Health Technologies and Services Policy, Alberta Health (Observer)  Andra Morrison, Program Development Officer, CADTH  Nina Frey, CADTH Secretariat CNESH Members

What should CNESH focus on

WHY A TOP 10 LIST? – WE HAVE OTHER EXAMPLES

EXAMPLES OF OTHER TOP 10 LISTS IN HEALTH CARE

Why not a Canadian top 10 list?

 Fall 2012-Network members agreed to develop an annual top 10 list of new and emerging health technologies for Canada.  Technologies that would be potential “game changers”.  List would be useful to support Canadian health care decision makers (patient, provider and policy maker) and HTA producers.  Support effective planning and decision making for introduction of new and innovative health technologies in the Canadian Health Care system.  Sought advice at CADTH 2013 workshop  Developed a rigorous process to ensure we were following best practices in horizon scanning What we did?

 Drugs, including but not limited to, biologics, blood products, vaccines, and prescription and non-prescription medicines.  Medical, dental, and surgical devices and procedures.  Diagnostics, including but not limited to, laboratory tests, screening programs, and diagnostic imaging.  Does not include:  Health human resources  Health system design  Electronic health-related technologies CADTH definition of Health Technology

 ‘ New’ refers to health technology that has been approved for clinical use for only a short time and is generally in the launch or early post- marketing stage of diffusion. Medical devices may be marketed but <10% diffused or localised to only a few centres.  Drugs are considered if they have not received Health Canada approval at the prioritization phase of the CNESH top 10 process.  ‘Emerging’ refers to a health technology that has not yet been approved by the regulator for use but has potential for significant impact on the health care system. Pharmaceuticals will usually be in phase II or III clinical trials; medical devices will be within six to nine months of marketing.  Emerging technologies could also include:  an existing health technology being investigated for a new indication, or  a health technology that is part of a group of developing technologies that, as a whole, may have an impact. New and Emerging Health Technologies

Some good press…

heading-watch-the-cnesh-top-10-watch-list-25184/2

uk%2Fmmlib%2Fincludes%2Fsendfile.php%3Fid%3D158&ei=kDUdVf2rJ9WwyATdxYCwAw&usg=AFQjCNHvN4NPZ59vp7MTwKactSCbwZlXwg&bvm=b v ,d.aWw

10. Finding time for network volunteer activities is very challenging 9. Getting agreement on process 8. Significant in-kind volunteer support 7. Convincing folks to nominate a technology 6. Start-up process is very time consuming Top 10 Lessons Learned from 2014…

5. Nominators exaggerate benefits/minimize harms 4. Significant staff resources are required 3. Very hard to screen out technologies 2. Expert involvement 1. With dedication and commitment it can be done! Top 10 Lessons Learned from 2014…

New and Improved Process NominationFiltrationVerification Prioritization Dissemination Evaluation

Andra Morrison Program Development Officer (Medical Devices) CADTH Panel Presenter

Top 10 New and Emerging Health Technologies Watch List 2015

Cédric Jehanno Vice-chair of CNESH INESSS Panel Presenter

Timing of the call for nominations and number of nominations we received Top 3 Lessons Learned from 2015…

nominations-for-2015-health-technology-watch-list

How can we increase the profile of CNESH and the top 10 list? Top 3 Lessons Learned from 2015…

What is the value add and impact of the list? Top 3 Lessons Learned from 2015…

 John Soloninka, HTX  Alison Drinkwater, Baxter Corporation  Alain Boisvert, Bristol Myers Squibb Panel Presenters

Top 10 Next Steps… 10. Approval of 3 year business plan 9. Feedback from nominators 8.Refinement of process and criteria 7. Involve collaborators in CNESH 6. Evaluation plan

Top 10 Next Steps… 5. Feedback from users 4. Publish our work 3. Monitor status of top 10 watch list 2. Develop 2016 top 10 list… 1. Take another (short) break!

ASK A QUESTION… GET a T-shirt